Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo  >  J-Oil Mills Inc    2613   JP3840000008

J-OIL MILLS INC

(2613)
  Report  
SummaryChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news

Patent Application Titled “Metabolic Syndrome Inhibitor” Published Online (USPTO 20190224260): J-Oil Mills Inc.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/14/2019 | 05:03pm EDT

2019 AUG 14 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity Daily News -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a patent application by the inventors MATSUMOTO, Shoji (Tokyo, Japan); NISHIMURA, Saki (Tokyo, Japan); SAKAINO, Masayoshi (Tokyo, Japan); YAMASHITA, Takatoshi (Tokyo, Japan), filed on June 26, 2017, was made available online on July 25, 2019.

The assignee for this patent application is J-Oil Mills Inc. (Tokyo, Japan).

Reporters obtained the following quote from the background information supplied by the inventors: “The number of so-called obese persons whose body fat accumulates more than necessary is increasing by synergy of increased lipid energy intake rate due to change of foods and excessive intake of foods and decreased consumption of intake enemy due to life inclined to be hypokinetic. Body fats include subcutaneous fats which accumulate under a skin, and visceral fats which accumulate around an internal organ in an intestine and an abdominal cavity. When the visceral fat excessively accumulates and lifestyle diseases such as hypertension, diabetes and dyslipidemia are compositely developed, the symptom is diagnosed as metabolic syndrome.

“The current diagnostic criteria for metabolic syndrome is that the followings are fulfilled:

“(i) visceral fat type obesity with a waist circumference exceeding a reference value (male: 85 cm, female: 90 cm); and

“(ii) at least two of the following abnormalities: (1) a neutral fat value of 150 mg/dL or higher, and/or an HDL-cholesterol value of lower than 40 mg/dL, (2) a systolic blood pressure of 130 mmHg or higher, and/or a diastolic blood pressure of 85 mmHg or higher, and (3) a fasting blood glucose of 110 mg/dL or higher.

“A person with metabolic syndrome is likely to advance arteriosclerosis, and as a result, the person is susceptible to serious diseases such as myocardial infarction and cerebral infarction. It is important to prevent and solve metabolic syndrome from the viewpoint of preventing these diseases.

“For preventing metabolic syndrome, attention is generally directed to a solution to inactivity, and improvement of dietary habit for lowering a lipid energy intake rate, e.g. diet, intake of low-fat foods, and cooking method using fats as little as possible.

“It has been also proposed to reduce body fats not by improvement of the lifestyle but by oral intake of a sate body fat-reducing agent. For example, body fat-reducing agents and body fat-burning agents comprising a dioxabicyclo[3.3.0]octane derivative (Patent Document 1), tea catechin (Patent Document 2), catechin and cacao polyphenol (Patent Document 3), asparagus extract (Patent Document 4) or the like as active ingredients, have been proposed.

“Phytosterols are known to inhibit absorption of cholesterol in a gastrointestinal tract and exhibit an action of decreasing a blood cholesterol level. A cholesterol forms a micelle together with a bile acid and is solubilized, and then taken up by small intestinal epithelial cells. Phytosterols also form a micelle together with a bile acid. Since dissolution of the sterols in micelles is limited, coexisting phytosterols competitively inhibit the micelle formation of the cholesterol (Non-Patent Documents 1 and 2) It has been proposed to use phytosterols as body cholesterol-reducing agents using this action mechanism. For example, Patent Document 5 discloses a lipid metabolism improver comprising diglycerides or diglycerides and phytosterols as active ingredients in a cholesterol synthesis inhibitor-resistant hyperlipidemia patient. Patent Document 6 discloses a body cholesterol-reducing agent comprising an oil obtained from a soybean raw material with an embryo content of 15 wt % or more, as an active ingredient.”

In addition to obtaining background information on this patent application, NewsRx editors also obtained the inventors’ summary information for this patent application: “Problem to be Solved

“The object of the present invention is to provide a metabolic syndrome inhibitor which can inhibit metabolic syndrome by oral intake similarly to the prior art described above.

“Solution to Problem

“The present inventors have found that a soybean hypocotyl oil has an action of inhibiting accumulation of body fats, particularly visceral fats and an action of suppressing increase of the blood neutral fat and thus it can be used for inhibiting metabolic syndrome, and this finding has led to the completion of the invention. That is, the present invention provides a metabolic syndrome inhibitor comprising a soybean hypocotyl oil as an active ingredient. The present invention is similar to the invention of Patent Document 6 in that they comprise the soybean hypocotyl oil as an active ingredient. However, the invention of Patent Document 6 is applied for the purpose of decrease of a body cholesterol level. The above-described action mechanism for decreasing the body cholesterol does not necessarily lead to inhibition of the body fat and visceral fat accumulation and inhibition of the blood neutral fat increase. Thus, Patent Document 6 disclosing only the body cholesterol-decreasing action does not teach a metabolic syndrome inhibitor which is an application of the present invention.

“The metabolic syndrome inhibitor is particularly a body fat accumulation inhibitor and/or a blood neutral fat increase inhibitor.

“The body fat accumulation inhibitor is particularly a visceral fat accumulation inhibitor.

“The metabolic syndrome inhibitor preferably contains 1 to 100 wt % of the soybean hypocotyl oil.

“Also, the present invention provides a fat or oil composition for inhibiting metabolic syndrome, which contains the metabolic syndrome inhibitor.

“Also, the present invention provides a food for inhibiting metabolic syndrome, which contains the metabolic syndrome inhibitor, or is cooked using the inhibitor.

“Also, the present invention provides a method for producing the metabolic syndrome inhibitor, including adding the soybean hypocotyl oil as an active ingredient.

“Also, the present invention provides a method for producing the food for inhibiting metabolic syndrome, including cooking the food by adding the metabolic syndrome inhibitor comprising the soybean hypocotyl oil as an active ingredient to a foodstuff.

“Effects of Invention

“The metabolic syndrome inhibitor of the present invention comprising soybean hypocotyl oil as an active ingredient exerts effects as a body fat accumulation inhibitor (in particular, a visceral fat accumulation inhibitor) and/or a blood neutral fat increase inhibitor, and as a result, metabolic syndrome can be improved or prevented. The soybean hypocotyl oil is known to have a blood cholesterol-decreasing action. The metabolic syndrome inhibitor of the present invention is superior to conventional metabolic syndrome inhibitors in that it simultaneously improves or prevents visceral fat type obesity and dyslipidemia associated with blood cholesterol and/or neutral fat. The metabolic syndrome inhibitor of the present invention can be greatly expected to prevent diseases developed due to progressed metabolic syndrome, e.g. arteriosclerosis, diabetic retinopathy, diabetic gangrene, diabetic nephropathy, renal failure, nephrosclerosis, uremia, angina pectoris, myocardial infarction, stroke, cerebral infarction and the like.

“By the metabolic syndrome inhibitor of the present invention, dietary restriction is not required for humans. In particular, fats and oils are foodstuffs which stimulate human gustatory senses, and thus, if fats and oils in foods are restricted for reducing the lipid energy, human dietary life becomes insipid. On the other hand, since the metabolic syndrome inhibitor of the present invention comprises fats and oils as active ingredients, it can inhibit metabolic syndrome while maintaining affluent human dietary life.”

The claims supplied by the inventors are:

“1-4. (canceled)

“5. A fat or oil composition for inhibiting metabolic syndrome, containing a metabolic syndrome inhibitor comprising a soybean hypocotyl oil as an active ingredient, wherein the metabolic syndrome is body fat accumulation.

“6. A food for inhibiting metabolic syndrome, containing a metabolic syndrome inhibitor comprising a soybean hypocotyl oil as an active ingredient, or is cooked using the inhibitor, wherein the metabolic syndrome is body fat accumulation.

“7. A method for producing a metabolic syndrome inhibitor, including adding a soybean hypocotyl oil as an active ingredient, wherein the metabolic syndrome is body fat accumulation.

“8. A method for producing a food for inhibiting metabolic syndrome, including cooking the food by adding a metabolic syndrome inhibitor comprising a soybean hypocotyl oil as an active ingredient to a foodstuff, wherein the metabolic syndrome is body fat accumulation.

“9. A method for inhibiting metabolic syndrome, including ingesting a metabolic syndrome inhibitor comprising a soybean hypocotyl oil as an active ingredient, wherein the metabolic syndrome is body fat accumulation.

“10. The method for inhibiting metabolic syndrome as claimed in claim 9, wherein the body fat accumulation is visceral fat accumulation.

“11. The method for inhibiting metabolic syndrome as claimed in claim 9, wherein the metabolic syndrome inhibitor contains 1 to 100 wt % of the soybean hypocotyl oil.”

For more information, see this patent application: MATSUMOTO, Shoji; NISHIMURA, Saki; SAKAINO, Masayoshi; YAMASHITA, Takatoshi. Metabolic Syndrome Inhibitor. Filed June 26, 2017 and posted July 25, 2019. Patent URL: http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220190224260%22.PGNR.&OS=DN/20190224260&RS=DN/20190224260

(Our reports deliver fact-based news of research and discoveries from around the world.)

Copyright © 2019 NewsRx LLC, Obesity Daily News, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on J-OIL MILLS INC
03/27J-OIL MILLS INC : Ex-dividend day for final dividend
FA
2018J-OIL MILLS INC : Ex-dividend day for interim dividend
FA
2018J-OIL MILLS INC : Ex-dividend day for final dividend
FA
2017J-OIL MILLS INC : Ex-dividend day for interim dividend
FA
2017J-OIL MILLS INC : Ex-dividend day for final dividend
FA
2016J-OIL MILLS INC : Ex-dividend day for interim dividend
FA
2016J-OIL MILLS INC : REVERSE SPLIT: 1 of 10
FA
2016J-OIL MILLS INC : Ex-dividend day for final dividend
FA
2015J-OIL MILLS INC : Ex-dividend day for interim dividend
FA
2015J-OIL MILLS INC : Ex-dividend day for final dividend
FA
More news
Financials (JPY)
Sales 2020 -
EBIT 2020 -
Net income 2020 -
Debt 2020 -
Yield 2020 -
P/E ratio 2020 -
P/E ratio 2021 -
Capi. / Sales2020 -
Capi. / Sales2021 -
Capitalization 64 841 M
Chart J-OIL MILLS INC
Duration : Period :
J-Oil Mills Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends J-OIL MILLS INC
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts
Average target price
Last Close Price 3 940,00  JPY
Spread / Highest target -
Spread / Average Target -
Spread / Lowest Target -
EPS Revisions
Managers
NameTitle
Fuminao Hachiuma President & Representative Director
Kenichi Tatsumi Director, Executive Officer & GM-Corporate
Katsuo Zento Director & General Manager-Sales
Yasuhiro Imai Independent Director
Kunihiko Kondo Director & Senior Managing Executive Officer
Sector and Competitors
1st jan.Capitalization (M$)
J-OIL MILLS INC4.51%607
SIME DARBY PLANTATION BHD--.--%7 895
IOI CORPORATION BHD--.--%6 338
AAK57.66%5 060
GOLDEN AGRI-RESOURCES LTD16.00%2 705
FIRST RESOURCES LTD-0.65%1 722